# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Windtree Therapeutics (NASDAQ:WINT) reported quarterly losses of $(20.91) per share which missed the analyst consensus estimate...
Windtree Therapeutics's (NYSE:WINT) short percent of float has fallen 17.46% since its last report. The company recently r...
Windtree Therapeutics shares are trading lower by 8.6% during Monday's session. The company announced it entered a $1M priv...
- SEC Filing